GSK plc’s proposal for use of single-arm trials to support accelerated approval of Jemperli (dostarlimab-gxly) in locally advanced rectal cancer gained backing from a majority of a US Food and Drug Administration advisory committee members on 9 February, despite reservations about the proposed primary endpoint.
Eight of the 13 members of the Oncologic Drugs Advisory Committee said a proposed single-arm, multicenter, Phase II study, in...





